Signal Transduction

References

 1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–5557.

 2. Cantrell DA. T cell receptor signal transduction pathways. Annu Rev Immunol. 1996;14:259–274.

 3. Burg DL, Furlong MT, Harrison ML, Geahlen RL. Interactions of Lyn with the antigen receptor during B cell activation. J Biol Chem. 1994;269:28136–28142.

 4. Metzger H. The receptor with high affinity for IgE. Immunol Revs. 1992;125:37–48.

538

TCR, BCR, Soluble Tyrosine Kinases and NFAT

 5. Dustin ML, Tseng SY, Varma R, Campi G. T cell-dendritic cell immunological synapses. Curr Opin Immunol. 2006;18:512–516.

 6. Gacon G, Fagard R, Boissel JP, et al. Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line. Biochem Biophys Res Commun. 1984;122: 563–570.

 7. Marth JD, Peet R, Krebs EG, Perlmutter RM. A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA. Cell. 1985;43:393–404.

 8. Barber EK, Dasgupta JD, Schlossman SF, Trevillyan JM, Rudd CE. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc Natl Acad Sci USA. 1989;86: 3277–3281.

 9. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004;23:7990–8000.

10.Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003;21:107–137.

11.Cantrell D. T cell antigen receptor signal transduction pathways. Annu Rev Immunol. 1996;14:259–274.

12.Neumeister EN, Zhu Y, Richard S, Terhorst C, Chan AC, Shaw AS. Binding of ZAP-70 to phosphorylated T-cell receptor z and h enhances its autophosphorylation and generates specific binding sites for SH2 domain-containing proteins. Mol Cell Biol. 1995;15:3171–3178.

13.Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998;92:83–92.

14.Braiman A, Barda-Saad M, Sommers CL, Samelson LE. Recruitment and activation of PLC 1 in T cells: a new insight into old domains. EMBO J. 2006;25:774–784.

15.Okamura H, Aramburu J, Garcia-Rodriguez C, et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell. 2000;6:539–550.

16.Feske S, Gwack Y, Prakriya M, et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature. 2006;441: 179–185.

17.Gwack Y, Sharma S, Nardone J, et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature. 2006;441:646–650.

18.Avots A, Buttmann M, Chuvpilo S, et al. CBP/p300 integrates Raf/Racsignaling pathways in the transcriptional induction of NF-ATc during T cell activation. Immunity. 1999;10:515–524.

19.Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis. 1999;34:1–13.

539

Signal Transduction

20.Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic -cell growth and function. Nature. 2006;443:345–349.

21.Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci U S A. 1989;86:1168–1172.

22.Swaminathan G, Tsygankov AY. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol. 2006;209:21–43.

23.Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell. 2004;14:289–301.

24.Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol. 2005;5:941–952.

25.Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol. 2006;176:2730–2738.

26.Morris RE. Rapamycin: FK506’s fraternal twin or distant cousin? Immunol Today 1991;12:137–140.

27.Myers MD, Dragone LL, Weiss A. Src-like adaptor protein down-regulates T cell receptor (TCR)-CD3 expression by targeting TCRz for degradation. J Cell Biol. 2005;170:285–294.

28.Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–572.

29.Schutz GJ, Kada G, Pastushenko VP, Schindler H. Properties of lipid microdomains in a muscle cell membrane visualized by single molecule microscopy. EMBO J. 2000;19:892–901.

30.Isaacs A, Lindemann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258–267.

31.Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol. 2006;8:907–922.

32.Chill JH, Quadt SR, Levy R, Schreiber G, Anglister J. The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure. 2003;11:791–802.

33.Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–264.

34.van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in mice lacking both / and interferon receptors. J Virol. 1995;69:4792–4796.

35.Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476–483.

36.Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: a current view. Int Immunol. 2005;17:1367–1378.

37.Genot E. Interferon and intracytoplasmic free calcium in hairy cell leukemia cells. Leuk-Lymphoma. 1994;12:373–381.

540

TCR, BCR, Soluble Tyrosine Kinases and NFAT

38.Kantarjian HM, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate versus interferon- -based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108: 1835–1840.

39.van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361–372.

40.Shual K, Ziemiecki A, Wilks AF, et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature. 1993;366:580–583.

41.Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591–594.

42.Timofeeva OA, Plisov S, Evseev AA, et al. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms’ tumor pathogenesis. Oncogene. 2006.

43.Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A. 1991;88:4171– 4175.

44.Haspel RL, Darnell JE. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. Proc Natl Acad Sci U S A. 1999;96:10188– 10193.

45.Zhong M, Henriksen MA, Takeuchi K, et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activationinactivation cycle. Proc Natl Acad Sci U S A. 2005;102:3966–3971.

46.Swameye I, Muller TG, Timmer J, Sandra O, Klingmuller U. Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc Natl Acad Sci USA. 2003;100:1028–1033.

47.Wu TR, Hong YK, Wang XD, et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem. 2002;277:47572–47580.

48.Tsui HW, Siminovitch KA, de Souza L, Tsui FWL. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nature. 1993;4:124–129.

49.Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 2006;71:713–721.

50.Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA. 1998;95:10626–10631.

51.Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol. 2005;5:593–605.

52.Warthin AS. Leukemia of the common fowl. J Infect Diseases. 1907;4:369– 380.

53.Warthin AS. Trans Assoc Am Physicians. 1904;19:421.

54.Ellermann V, Bang O. Experimentelle leukämie bei hünern. Zentr Bakteriol Parasitenk. 1908;4:595–609.

541

Signal Transduction

55.Kidd JG, Beard JW, Rous P. Serological reactions with a virus causing rabbit papllomas which become cancerous. J Exp Med. 1936;64:63–77.

56.Doherty J, Freund R. Polyomavirus large T antigen overcomes p53 dependent growth arrest. Oncogene. 1997;14:1923–1931.

57.Wilkerson VW, Bryant DL, Parsons JT. Rous sarcoma virus variants that encode src proteins with an altered carboxy terminus are defective for cellular transformation. J Virol. 1985;55:314–321.

58.Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell. 1999;3:629–638.

59.Cowan-Jacob SW, Fendrich G, Manley PW, et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure. 2005;13:861–871.

60.Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689.

61.Spector DH, Varmus HE, Bishop JM. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc Natl Acad Sci U S A. 1978;75:4102–4106.

62.Bishop JM, Baker B, Fujita D, et al. Genesis of a virus-transforming gene.

Natl Cancer Inst Monogr. 1978:219–223.

63.Poulin DL, DeCaprio JA. Is there a role for SV40 in human cancer? J Clin Oncol 2006;24:4356–4365.

64.Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309–1312.

65.Meydan N, Grunberger T, Shahar M, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645–648.

66.Kawabuchi M, Satomi Y, Takao T, et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 2000;404:999–1003.

67.De Luca A, Baldi A, Esposito V, et al. The retinoblastoma gene family pRb/ p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med. 1997;3:913–916.

542